Diabinese — Competitive Intelligence Brief

Diabinese (CHLORPROPAMIDE) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Sulfonylurea. Area: Metabolic.

marketed Sulfonylurea Sulfonylurea receptor 1, Kir6.2 Metabolic Small molecule

Target snapshot

Diabinese (CHLORPROPAMIDE) — Pfizer.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Diabinese TARGET	CHLORPROPAMIDE	Pfizer	marketed	Sulfonylurea	Sulfonylurea receptor 1, Kir6.2	1958-01-01
Starlix	NATEGLINIDE	Novartis	marketed	Glinide [EPC]	Sulfonylurea receptor 1, Kir6.2	2000-01-01
Amaryl	GLIMEPIRIDE	Sanofi	marketed	Sulfonylurea [EPC]	Sulfonylurea receptor 1, Kir6.2	1995-01-01
Micronase	glibenclamide	Sanofi	marketed	Sulfonylurea	Sulfonylurea receptor 1, Kir6.2	1984-01-01
Glucotrol	GLIPIZIDE	Pfizer	marketed	Sulfonylurea [EPC]	Sulfonylurea receptor 1, Kir6.2	1984-01-01
Proglycem	DIAZOXIDE		marketed	diazoxide	Sulfonylurea receptor 1, Kir6.2	1973-01-01
Dymelor	ACETOHEXAMIDE	Eli Lilly	marketed	acetohexamide	Sulfonylurea receptor 1, Kir6.2	1964-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Sulfonylurea class)

1. Merck Sharp & Dohme LLC · 6 drugs in this class
2. Pfizer · 2 drugs in this class
3. Sanofi · 2 drugs in this class
4. Janssen Research & Development, LLC · 1 drug in this class
5. Samsung Medical Center · 1 drug in this class
6. Servier Affaires Médicales · 1 drug in this class
7. The George Institute · 1 drug in this class
8. · 1 drug in this class
9. University of Glasgow · 1 drug in this class
10. GRADE Study Group · 1 drug in this class